Since the publication of our Executive Informational Overview® (EIO) on Amarantus BioScience Holdings, Inc. (AMBS-OTC) in early September 2014, the company has advanced development of each of its three lead programs. Amarantus published data from a 72-patient study of the LymPro Test® demonstrating the test’s accuracy at identifying patients with moderate-to-severe Alzheimer's Disease versus healthy controls, completed enrollment of an expanded 140-patient study of LymPro for which results are expected by mid-December 2014, submitted its Phase 2b trial design for Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia to the FDA for review and written feedback, and submitted an Orphan Drug application to the FDA for MANF in retinitis pigmentosa, a degenerative eye disease. By the end of 2014, Amarantus expects to be able to launch the LymPro Test® for research markets (Investigational Use Only), and believes it can use the data from the expanded 140-patient LymPro study in support of a broader product launch in 2015.